November 8, 2023
- June 5, 2023 - Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional). See NOFO RFA-HG-23-018
National Human Genome Research Institute (NHGRI)
The purpose of this Notice is to inform potential applicants that the National Human Genome Research Institute is extending the first receipt date of RFA-HG-23-018: Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional) from November 8, 2023 to December 19, 2023 effective immediately.
The following section of RFA-HG-23-018 have been updated (changes shown in bold italics):
Part 1. Overview Information:
Key Dates
Posted Date June 05, 2023
Open Date (Earliest Submission Date) November 19, 2023
Letter of Intent Due Date(s) 30 days prior to the application receipt date.
Application Due Dates | Review and Award Cycles | ||||
|---|---|---|---|---|---|
New | Renewal / Resubmission / Revision (as allowed) | AIDS | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
| December 19, 2023 | Not Applicable | Not Applicable | March 2024 | May 2024 | July 2024 |
| July 08, 2024 | July 08, 2024 | Not Applicable | November 2024 | January 2025 | April 2025 |
| July 08, 2025 | July 08, 2025 | Not Applicable | November 2025 | January 2026 | April 2026 |
All applications are due by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Expiration Date July 09, 2025
All other aspects of this application remain the same.
This change is effective immediately.
NHGRI encourages inquiries concerning this funding opportunity and welcomes the opportunity to answer questions from potential applicants.
Inquiries:
Lucia Hindorff, Ph.D.
National Human Genome Research Institute (NHGRI)
Telephone: 240-271-1509
Email: [email protected]
and Human Services (HHS)
